PubMed Health⌕ Search

Biomedical subjects

D Stubbs

Publications and source records attributed to D Stubbs.

11 recordsLinked to original sources
PubMed1989

The contribution of ergonomics to the rehabilitation of back pain patients.

The role of ergonomics in existing rehabilitation programmes is considered through a review of studies undertaken both in the United Kingdom and elsewhere. In general, little consideration has been paid to what the rehabilitees are undertaking in their work or to how intervention at the workplace might be implemented. This occurs despite the evidence that ergonomic advice has been shown to be beneficial. Current approaches to rehabilitation stress the need for the patient to resume normal activities as soon as possible. It seems also prudent to identify ergonomic mismatches in the workplace as soon as possible during rehabilitation in order to reduce the number of repeat attacks. A number of examples have been presented which illustrate how ergonomics can help, and the dangers of inappropriate or delayed interventions. The occupational physician is considered to be a key individual in initiating ergonomic interventions. This is in keeping with the International Labour Office model of occupational health services.

Adult↗
PubMed1989

Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen.

The treatment of human periodontal diseases relies on mechanical and antimicrobial suppression of the etiologic bacteria. The ability to alter the progression of periodontitis by additionally blocking host pathways involved in the destructive process is an area of current research. Prostaglandins and other metabolites of arachidonic acid are believed to be important host mediators of the bone resorption of diseases such as periodontitis. We have previously examined the effect of inhibitors of prostaglandin production, non-steroidal anti-inflammatory drugs (NSAIDs), on inhibiting alveolar bone loss in beagles. The present study was designed to examine the effect of the NSAID, flurbiprofen, on slowing the radiographic loss of alveolar bone in the human. Fifty-six individuals with radiographic evidence of alveolar bone loss were recruited for study. Forty-four patients remained in the study for the data analysis of loss of alveolar bone. Following a 6 month baseline pretreatment period to measure the radiographic progression of bone loss, half of the patients were administered flurbiprofen, 50 mg. b.i.d., while half were administered a placebo. All patients received a subgingival scaling and pumice by a hygienist every 6 months. The rate of alveolar bone loss in a 2 year treatment period was compared to the baseline 6 month pretreatment period within and between patient groups. Throughout the study, teeth exhibiting obvious loss of bone were exited from study and treated with conventional mechanical therapy. At the end of the pretreatment period both patient groups had a similar mean rate of alveolar bone loss.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1976

Role of the renin-angiotensin system in dogs with perinephritis hypertension.

Cellophane perinephritis hypertension was produced in four dogs, while five additional dogs served as normotensive controls. A competitive antagonist of angiotensin II, 1-sarcosine-8-alanine angiotensin II, was infused iv into these conscious dogs at a rate of 6 mug/min/kg of body weight for 45 min. Arterial pressure averaged 170 +/- 11 (SEM) mm Hg in the dogs with perinephritic hypertension, and was not altered significantly during infusion of the angiotensin antagonist. In the normal dogs the arterial pressure averaged 100 +/- 10 mm Hg and likewise, did not change during administration of the angiotensin analog. Plasma renin activity values were essentially the same in these two groups of dogs and did not change during infusion of the angiotensin antagonist. These studies provide strong evidence that the renin-angiotensin system is not involved in maintaining the elevated arterial pressure in dogs with chronic hypertension produced by cellophane perinephritis.

Angiotensin II↗